This Article Full Text Full Text (PDF) All Versions of this Article: 34/8/2072    most recent 01.STR.0000082381.23938.0Ev1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by De Schryver, E.L.L.M. Articles by van Gijn, J. Search for Related Content PubMed PubMed Citation Articles by De Schryver, E.L.L.M. Articles by van Gijn, J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Cardiac Arrest Heart Attack Stroke Vascular Diseases Related Collections Antiplatelets Secondary prevention Primary and Secondary Stroke Prevention

(Stroke. 2003;34:2072.)
© 2003 American Heart Association, Inc.

Comments, Opinions, and Reviews

Cochrane Review: Dipyridamole for Preventing Major Vascular Events in Patients With Vascular Disease

From the University Medical Center Utrecht, Utrecht, Netherlands.

Correspondence to A. Algra, MD, University Medical Center Utrecht, D.01.335, PO Box 85500, 3508 GA Utrecht, Netherlands. E-mail a.algra{at}azu.nl

Background— Patients enrolled in clinical trials after nondisabling cerebral ischemia have an annual risk of vascular events (death from all vascular causes, nonfatal stroke, or nonfatal myocardial infarction) of 4% to 11%. Aspirin reduces the incidence by 13%. Many trials in patients presenting with vascular disease investigated the efficacy of (addition of) dipyridamole in secondary prevention. We systematically compared the efficacy and safety of dipyridamole versus control in the presence and absence of other antiplatelet drugs in clinical trials on the secondary prevention of vascular events in patients with vascular disease.

Summary of Review— Randomized trials with concealed treatment allocation in patients with a nonembolic arterial vascular disease were selected. Therapy consisted of dipyridamole in the presence or absence of other antiplatelet drugs compared with no drug or an antiplatelet drug(s) other than dipyridamole. Twenty-six trials were included, with a total of 19 842 patients. Dipyridamole was not more efficacious in the prevention of vascular death (relative risk [RR], 1.02; 95% CI, 0.90 to 1.17). It appeared more efficacious in the prevention of vascular events (RR, 0.90; 95% CI, 0.83 to 0.98), but this result only reached statistical significance because of 1 large trial in patients presenting with cerebral ischemia. Combination treatment of dipyridamole and aspirin compared with aspirin had an RR of 1.03 (95% CI, 0.87 to 1.22) for vascular death and an RR of 0.90 (95% CI, 0.80 to 1.00) for vascular events.

Conclusions— For patients who presented with arterial vascular disease, there was no evidence that dipyridamole, in the presence or absence of another antiplatelet drug (chiefly aspirin), reduced the risk of vascular death, although it may reduce the risk of further vascular events. However, this benefit was found only in a single large trial and only in patients presenting after cerebral ischemia. There was no evidence that dipyridamole alone was more efficacious than aspirin. Further trials comparing the effects of the combination of dipyridamole plus aspirin with aspirin alone are justified.

Key Words: dipyridamole • stroke • vascular diseases

This article has been cited by other articles:

				A. Gamboa, R. Abraham, A. Diedrich, C. Shibao, S. Y. Paranjape, G. Farley, and I. Biaggioni Role of Adenosine and Nitric Oxide on the Mechanisms of Action of Dipyridamole Stroke, October 1, 2005; 36(10): 2170 - 2175. [Abstract] [Full Text] [PDF]

				G. J Hankey Review: dipyridamole given with or without aspirin reduces recurrent stroke Evid. Based Med., August 1, 2005; 10(4): 113 - 113. [Full Text] [PDF]

				H. Derendorf, C. P. VanderMaelen, R.-S. Brickl, T. R. MacGregor, and W. Eisert Dipyridamole Bioavailability in Subjects With Reduced Gastric Acidity J. Clin. Pharmacol., July 1, 2005; 45(7): 845 - 850. [Abstract] [Full Text] [PDF]

				G. J. Hankey and J. W. Eikelboom Adding aspirin to clopidogrel after TIA and ischemic stroke: Benefits do not match risks Neurology, April 12, 2005; 64(7): 1117 - 1121. [Abstract] [Full Text] [PDF]

				J. Leonardi-Bee, P. M.W. Bath, M.-G. Bousser, A. Davalos, H.-C. Diener, B. Guiraud-Chaumeil, J. Sivenius, F. Yatsu, M. E. Dewey, and on behalf of the Dipyridamole in Stroke Collaborat Dipyridamole for Preventing Recurrent Ischemic Stroke and Other Vascular Events: A Meta-Analysis of Individual Patient Data From Randomized Controlled Trials Stroke, January 1, 2005; 36(1): 162 - 168. [Abstract] [Full Text] [PDF]

				J. J. F. P. Luiken, S. L. M. Coort, J. Willems, W. A. Coumans, A. Bonen, and J. F. C. Glatz Dipyridamole Alters Cardiac Substrate Preference by Inducing Translocation of FAT/CD36, but Not That of GLUT4 Mol. Pharmacol., March 1, 2004; 65(3): 639 - 645. [Abstract] [Full Text] [PDF]